JS25was obtained from the scaffold of BMX-IN-1, a recently discoveredmolecule that has been shown to also inhibit BTK, as part of our effortsto identify regions of the molecule that could be modulated for improvedefficacy and selectivity.23,24 Initially, we had exploredthe JS25 potential for treating prostate cancer, but later experimentsrevealed that JS25 was highly selective for BTK, and therefore, itcould have therapeutic importance in blood malignancies that derivefrom BTK’s abnormal expression. This evidence concerns the gene BTK and Familial prostate cancer.